$25 Million Deal! NVIDIA-Backed AI Drugmaker Iambic Therapeutics Announces New Collaboration and Files IPO Prospectus

Jul 10, 2025 18:48 CST Updated 18:48

Iambic Therapeutics

Small Molecule Therapy Developer

Revolution

Antitumor Drug Developer

Today, NVIDIA's market value has reached $4 trillion, becoming the first company in the world to break the $4 trillion market value.

Similarly, the AI pharmaceutical company supported by NVIDIAIambic Therapeutics, reached a new cooperation.

It is reported that Iambic TherapeuTICS and NASDAQ-listed biopharmaceutical companiesRevolution MedicinesReach an agreement,Leverage its AI-driven platform to develop new drugs.

According to the agreement,Iambic will use the structures and molecular libraries provided by Revolution Medicines to train a customized version.Protein-ligand structure prediction model. Additionally,Revolution will also access other chemical models of the company.PropANE。

Iambic Therapeutics will receive $25 million in upfront and milestone payments to support NeuralPLexer model-related services for protein structure prediction.

Iambic Therapeutics was foundedAt the beginning of 2020, the company was founded by two chemistry professors and is headquartered in San Diego, USA.

In June 2024, the company completed a $150 millionSeries B financing, the total amount of financing has also accumulated to$200 million, investors includeNVIDIA, the new global market value leader.

Iambic Therapeutics has built a nameFor InsightA R&D platform combining artificial intelligence and physics for creating more reliable and accurate models to explore the field of chemistry more deeply. The platform is mainly divided into four parts.

NeuralPLexer: For predicting protein-ligand complexes, including conformational responses to binding, revealing new mechanisms of action, allosteric and cryptic pockets

OrbNet: AI-Accelerated Quantum Chemistry for Calculating Protein-Ligand Binding Energy

PropANE: A lead compound parameter optimization model capable of training dozens of drug properties

Magnet: Molecular Design Generation

The company's molecular design software Magnet can perform tasks in one go.1024 molecules, and combined with wet lab experiments to refine predictive molecules through testing results,A design-build-test cycle typically takes 9 days.

NVIDIA is not onlyIambic Therapeutics' investors, both parties began to collaborate on the development of AI + biomedicine models.Iambic'sPrediction of Protein-Ligand Complex ModelsNeuralPLexer Already deployed to NVIDIABioNeMo NIM.

—The End—

Recommended Reading